BRPI0606112B8 - 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos - Google Patents

3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos

Info

Publication number
BRPI0606112B8
BRPI0606112B8 BRPI0606112A BRPI0606112A BRPI0606112B8 BR PI0606112 B8 BRPI0606112 B8 BR PI0606112B8 BR PI0606112 A BRPI0606112 A BR PI0606112A BR PI0606112 A BRPI0606112 A BR PI0606112A BR PI0606112 B8 BRPI0606112 B8 BR PI0606112B8
Authority
BR
Brazil
Prior art keywords
hetero
aryl
hydroxy
amino
pharmaceutical composition
Prior art date
Application number
BRPI0606112A
Other languages
English (en)
Inventor
Leblond Bertrand
Beausoleil Eric
E Donello John
Taverne Thierry
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0606112A2 publication Critical patent/BRPI0606112A2/pt
Publication of BRPI0606112B1 publication Critical patent/BRPI0606112B1/pt
Publication of BRPI0606112B8 publication Critical patent/BRPI0606112B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

3-h eteroaril-3-hidróxi-2-amino-propilaminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica. a presente invenção refere-se a compostos da fórmula onde as variáveis têm o significado definido no relatório descritivo têm efeito analgésico ou imunoestimulante em mamíferos.
BRPI0606112A 2005-01-26 2006-01-25 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos BRPI0606112B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64727105P 2005-01-26 2005-01-26
US60/647,271 2005-01-26
PCT/US2006/002570 WO2006081276A1 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity

Publications (3)

Publication Number Publication Date
BRPI0606112A2 BRPI0606112A2 (pt) 2009-06-02
BRPI0606112B1 BRPI0606112B1 (pt) 2021-02-23
BRPI0606112B8 true BRPI0606112B8 (pt) 2021-05-25

Family

ID=36250723

Family Applications (5)

Application Number Title Priority Date Filing Date
BRPI0607379A BRPI0607379B8 (pt) 2005-01-26 2006-01-25 composição farmacêutica de efeito analgésico
BRPI0606111A BRPI0606111B8 (pt) 2005-01-26 2006-01-25 amidas de ácido 3-aril-3-hidróxi-2-amino-propiônico, 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados tendo atividade analgésica e/ou imunoestimulante
BRPI0607304-2A BRPI0607304A2 (pt) 2005-01-26 2006-01-25 compostos tendo atividade analgésica e/ou imunoestimulante
BRPI0606112A BRPI0606112B8 (pt) 2005-01-26 2006-01-25 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos
BR122018068138A BR122018068138B8 (pt) 2005-01-26 2006-01-25 Amidas de ácido 3-aril-3-hidróxi-2-amino-propiônico, 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados tendo atividade analgésica e/ou imunoestimulante

Family Applications Before (3)

Application Number Title Priority Date Filing Date
BRPI0607379A BRPI0607379B8 (pt) 2005-01-26 2006-01-25 composição farmacêutica de efeito analgésico
BRPI0606111A BRPI0606111B8 (pt) 2005-01-26 2006-01-25 amidas de ácido 3-aril-3-hidróxi-2-amino-propiônico, 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados tendo atividade analgésica e/ou imunoestimulante
BRPI0607304-2A BRPI0607304A2 (pt) 2005-01-26 2006-01-25 compostos tendo atividade analgésica e/ou imunoestimulante

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018068138A BR122018068138B8 (pt) 2005-01-26 2006-01-25 Amidas de ácido 3-aril-3-hidróxi-2-amino-propiônico, 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados tendo atividade analgésica e/ou imunoestimulante

Country Status (19)

Country Link
US (11) US8013000B2 (pt)
EP (7) EP1841423B1 (pt)
JP (6) JP5042040B2 (pt)
KR (1) KR101395382B1 (pt)
CN (2) CN102718748B (pt)
AT (3) ATE549020T1 (pt)
AU (4) AU2006209197A1 (pt)
BR (5) BRPI0607379B8 (pt)
CA (4) CA2595519C (pt)
DE (1) DE602006012801D1 (pt)
DK (3) DK1841756T3 (pt)
ES (5) ES2380904T3 (pt)
HU (1) HUE028654T2 (pt)
MX (1) MX2007008955A (pt)
NZ (1) NZ556614A (pt)
PL (2) PL383715A1 (pt)
RU (1) RU2433999C2 (pt)
WO (4) WO2006081273A1 (pt)
ZA (1) ZA200706010B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
ES2380904T3 (es) 2005-01-26 2012-05-21 Allergan, Inc. Composiciones farmacéuticas que tienen un efecto analgésico y contienen 1-bencil-1-hidroxi-2,3-diamino-propil aminas, amidas del ácido 3-bencil-3-hidroxi-2-amino propiónico o compuestos relacionados
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
WO2008011485A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain
WO2008011478A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
PT2481407T (pt) * 2007-03-06 2018-12-28 Allergan Inc Compostos para utilização no tratamento de distúrbios cognitivos
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101778628B (zh) * 2007-07-17 2013-02-06 阿勒根公司 治疗焦虑的方法
ES2660690T3 (es) 2007-10-05 2018-03-23 Genzyme Corporation Método para tratar poliquistosis renales con derivados de ceramida
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
WO2011009061A1 (en) 2009-07-17 2011-01-20 Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
BR112012006027A2 (pt) * 2009-09-16 2019-09-24 Allergan Inc composições e métodos para tratar distúrbios de motilidade gastrointestinal.
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders
WO2011034912A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating spasticity
MX2012005759A (es) 2009-11-18 2012-10-03 Fab Pharma S A S Acrilamidas heterociclicas novedosas y su uso como farmacos.
JP6486358B2 (ja) 2013-08-15 2019-03-20 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用
CN105745206B (zh) 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
JP6152816B2 (ja) * 2014-03-26 2017-06-28 ソニー株式会社 半導体デバイス、表示パネル、表示装置、電子装置、および、半導体デバイスの製造方法
DE102015217629A1 (de) * 2015-09-15 2017-03-16 Tridonic Gmbh & Co Kg PFC-Modul für lückenden Betrieb
EP3805206A1 (en) * 2019-10-08 2021-04-14 Novaled GmbH Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2514380A (en) * 1946-12-26 1950-07-11 Hoffmann La Roche Diamines and method of production
DE1001261C2 (de) * 1954-08-05 1957-07-04 Thomae Gmbh Dr K Verfahren zur Herstellung von basischen Estern endocyclisch substituierter Mandelsaeuren und ihren Salzen
US2918466A (en) * 1955-05-24 1959-12-22 Univ St Johns Antimicrobial chemical compounds derived from alkoxyphenyl glycidic acid
US3065265A (en) * 1957-07-04 1962-11-20 Hoffmann La Roche Amino acid hydrazides
SU1063026A1 (ru) 1982-05-19 1990-12-07 Институт биохимии АН ЛитССР N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью
EP0144290A3 (de) * 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
JPS60132935A (ja) 1983-12-20 1985-07-16 Sumitomo Chem Co Ltd フエニルセリン誘導体及びその製造方法
JPS61145148A (ja) 1984-12-19 1986-07-02 Sumitomo Seiyaku Kk フエニルセリン誘導体
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
GB8622352D0 (en) * 1986-09-17 1986-10-22 Zambeleetti Spa Dr L Compounds
JPH02250845A (ja) 1989-03-22 1990-10-08 Sumitomo Pharmaceut Co Ltd ３―（４―フルオロフェニル）プロピオンアルデヒドの製造方法
DE69219354T2 (de) * 1991-05-10 1997-10-23 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
JPH0550499A (ja) 1991-08-27 1993-03-02 Kuwabara Yasunaga 成形型内におけるトリミング方法及び容器
US6696486B1 (en) * 1992-01-22 2004-02-24 Glaxo Group Limited Medical use for atypical β-adrenoceptor agonists
CN1128951A (zh) 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
JPH09506610A (ja) 1993-12-17 1997-06-30 ディーエスエム エヌ．ブイ． フェニルセリンアミド、及びフェニルセリン／フェニルセリンアミド の調製
CN1152907A (zh) * 1994-06-10 1997-06-25 生化学工业株式会社 2-酰胺基丙醇化合物及其药物组合物
WO1996009405A1 (en) * 1994-09-19 1996-03-28 The Board Of Trustees Of Leland Stanford, Junior University Treatment of plasmodium
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
FR2732894B1 (fr) 1995-04-13 1997-07-04 Sanofi Sa Nouvelle utilisation de composes agonistes beta9-adrenergiques
JPH08337569A (ja) * 1995-06-15 1996-12-24 Sankyo Co Ltd 鎮痛活性物質
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
DE19601745C1 (de) 1996-01-19 1997-10-09 Gruenenthal Gmbh Verfahren zur Racematspaltung von Tramadol
EP0848059A1 (en) * 1996-12-12 1998-06-17 Vetigen Mammalian ICYP (Iodocyanopindolol) receptor and its applications
WO1998033501A1 (en) 1997-01-31 1998-08-06 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
US6573387B1 (en) 1997-03-21 2003-06-03 The Scripps Research Institute Synthesis of α,β-substituted amino amides, esters, and acids
JP4036500B2 (ja) * 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US6617340B1 (en) * 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
ES2216644T3 (es) * 1999-10-06 2004-10-16 Torrent Pharmaceuticals Ltd Derivados de piridinio utiles para el tratamiento de complicaciones vasculares relacionadas con el envejecimiento y procedimiento de preparacion y uso de los mismos.
SE9904197D0 (sv) 1999-11-22 1999-11-22 Amersham Pharm Biotech Ab A method for anion exchange adsorption on matrices carrying mixed mode ligands
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
WO2001047874A1 (en) 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
US6380398B2 (en) * 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
KR20000063913A (ko) 2000-08-10 2000-11-06 하현준 아지리딘으로부터 1,2-디아미노프로판 알코올을 제조하는방법
BR0206400A (pt) 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
CA2453978C (en) * 2001-07-16 2011-10-11 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
JP2006021997A (ja) 2002-07-09 2006-01-26 Ono Pharmaceut Co Ltd ｃｙｓＬＴ１／ｃｙｓＬＴ２両受容体拮抗性呼吸器疾患治療剤
AU2003297564A1 (en) * 2002-12-04 2004-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2851462A1 (en) 2003-01-08 2004-07-29 University Of Washington Antibacterial agents
US7504423B2 (en) * 2003-12-11 2009-03-17 Mitsubishi Tanabe Pharma Corporation α-amino acid derivatives and use thereof as medicines
CA2548313A1 (en) 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
EP1781331A1 (en) 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
DE102004053409A1 (de) 2004-11-05 2006-05-11 Bayer Healthcare Ag Verfahren zur gezielten Herstellung von Lysobactinfragmenten
ES2380904T3 (es) 2005-01-26 2012-05-21 Allergan, Inc. Composiciones farmacéuticas que tienen un efecto analgésico y contienen 1-bencil-1-hidroxi-2,3-diamino-propil aminas, amidas del ácido 3-bencil-3-hidroxi-2-amino propiónico o compuestos relacionados
US7858825B2 (en) * 2007-02-15 2010-12-28 Colorado State University Research Foundation Acid and base stable diphenylmethanol derivatives and methods of use
PT2481407T (pt) * 2007-03-06 2018-12-28 Allergan Inc Compostos para utilização no tratamento de distúrbios cognitivos
US8173683B2 (en) * 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
WO2008109286A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
CN101778628B (zh) * 2007-07-17 2013-02-06 阿勒根公司 治疗焦虑的方法
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
US8124648B2 (en) * 2008-05-20 2012-02-28 Allergan, Inc. Therapeutic lactams
WO2011034912A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating spasticity
BR112012006027A2 (pt) * 2009-09-16 2019-09-24 Allergan Inc composições e métodos para tratar distúrbios de motilidade gastrointestinal.
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders

Also Published As

Publication number Publication date
BRPI0606112A2 (pt) 2009-06-02
BR122018068138B8 (pt) 2022-02-08
CA2595544C (en) 2013-04-02
JP5107058B2 (ja) 2012-12-26
BR122018068138B1 (pt) 2021-09-08
CA2595522A1 (en) 2006-08-03
WO2006081276A1 (en) 2006-08-03
EP2474534B1 (en) 2015-07-29
CN102718748A (zh) 2012-10-10
US20080312236A1 (en) 2008-12-18
EP2198864A1 (en) 2010-06-23
JP2008528600A (ja) 2008-07-31
US20090088433A1 (en) 2009-04-02
JP2012162547A (ja) 2012-08-30
BRPI0606111B1 (pt) 2020-12-15
JP2008528601A (ja) 2008-07-31
EP1841423B1 (en) 2010-03-10
JP5042039B2 (ja) 2012-10-03
DE602006012801D1 (de) 2010-04-22
ES2565236T3 (es) 2016-04-01
EP1841743B1 (en) 2016-01-20
US20090036436A1 (en) 2009-02-05
CA2595544A1 (en) 2006-08-03
ATE549020T1 (de) 2012-03-15
EP2489658A1 (en) 2012-08-22
BRPI0607379B1 (pt) 2020-06-30
PL1841743T3 (pl) 2016-06-30
BRPI0607304A2 (pt) 2009-08-25
RU2433999C2 (ru) 2011-11-20
HUE028654T2 (en) 2016-12-28
US20110288094A1 (en) 2011-11-24
BRPI0606111B8 (pt) 2021-05-25
CA2595542A1 (en) 2006-08-03
BRPI0606111A2 (pt) 2009-06-02
CA2595522C (en) 2013-09-10
EP1841756A1 (en) 2007-10-10
AU2006209209B2 (en) 2012-07-19
BRPI0607379A2 (pt) 2009-09-01
US9828349B2 (en) 2017-11-28
AU2006209208B2 (en) 2012-08-23
AU2006209197A1 (en) 2006-08-03
ES2371265T3 (es) 2011-12-29
US8927589B2 (en) 2015-01-06
JP5042040B2 (ja) 2012-10-03
US20160083371A1 (en) 2016-03-24
CA2595519C (en) 2013-10-29
WO2006081280A1 (en) 2006-08-03
DK1841423T3 (da) 2010-06-07
WO2006081252A3 (en) 2006-12-28
ES2380904T3 (es) 2012-05-21
CN101151248A (zh) 2008-03-26
ZA200706010B (en) 2009-04-29
US8153666B2 (en) 2012-04-10
EP2474534A1 (en) 2012-07-11
CN102718748B (zh) 2016-06-22
EP1841756B1 (en) 2011-09-07
AU2006209207B2 (en) 2012-08-23
US20130310383A1 (en) 2013-11-21
WO2006081273A1 (en) 2006-08-03
WO2006081276A8 (en) 2007-05-03
EP1841423A2 (en) 2007-10-10
BRPI0607379B8 (pt) 2021-05-25
ATE523491T1 (de) 2011-09-15
DK1841743T3 (en) 2016-03-14
BRPI0606112B1 (pt) 2021-02-23
JP2008528602A (ja) 2008-07-31
AU2006209207C1 (en) 2013-05-23
US20120225881A1 (en) 2012-09-06
WO2006081273A8 (en) 2007-03-01
US20130202653A1 (en) 2013-08-08
RU2007128313A (ru) 2009-03-10
JP2008528596A (ja) 2008-07-31
US8513288B2 (en) 2013-08-20
US8013000B2 (en) 2011-09-06
PL383715A1 (pl) 2008-05-12
EP2198864B1 (en) 2012-03-14
ATE460159T1 (de) 2010-03-15
US20120157497A1 (en) 2012-06-21
AU2006209208A1 (en) 2006-08-03
US9278943B2 (en) 2016-03-08
NZ556614A (en) 2010-10-29
EP1841742A1 (en) 2007-10-10
US8835463B2 (en) 2014-09-16
KR101395382B1 (ko) 2014-05-14
EP1841742B1 (en) 2013-10-30
US20130005717A1 (en) 2013-01-03
ES2340196T3 (es) 2010-05-31
CA2595519A1 (en) 2006-08-03
HK1145628A1 (en) 2011-04-29
KR20070098946A (ko) 2007-10-05
US8431599B2 (en) 2013-04-30
AU2006209209A1 (en) 2006-08-03
MX2007008955A (es) 2007-09-18
EP2489658B1 (en) 2014-04-09
US8288556B2 (en) 2012-10-16
CN101151248B (zh) 2012-06-20
US9399628B2 (en) 2016-07-26
JP2012162546A (ja) 2012-08-30
HK1173721A1 (en) 2013-05-24
AU2006209207A1 (en) 2006-08-03
DK1841756T3 (da) 2011-10-17
ES2436612T3 (es) 2014-01-03
WO2006081252A2 (en) 2006-08-03
JP5039564B2 (ja) 2012-10-03
EP1841743A1 (en) 2007-10-10
US20090318499A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
BRPI0606112B8 (pt) 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BRPI0607728A2 (pt) complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
CR20110016A (es) Compuestos quimicos 251
EA200870019A1 (ru) Лактамовые соединения и способы их применения
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
IL195030A (en) Dpp iv inhibitor formulations
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
BRPI0508464B8 (pt) sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BRPI0716495A2 (pt) (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.
CY1110046T1 (el) Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
BRPI0820985A2 (pt) Composto derivado de 5-aminociclometil-oxazondin-2-ona, medicamento e composição farmacêutica que os contém e uso dos mesmos
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
CL2010001421A1 (es) Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2864 DE 25-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.